Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. SGMO Peers
See (SGMO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SGMO | $0.47 | +4.44% | 109.59M | -0.96 | -$0.49 | N/A |
| VRTX | $438.65 | +0.98% | 112.64B | -114.83 | -$3.82 | N/A |
| REGN | $594.32 | +1.59% | 63.09B | 15.10 | $39.37 | +0.15% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $285.31 | +0.67% | 37.20B | -135.86 | -$2.10 | N/A |
| ARGX | $565.63 | +0.69% | 34.54B | 34.47 | $16.41 | N/A |
| BNTX | $92.77 | +0.47% | 22.30B | -26.06 | -$3.56 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| RPRX | $34.02 | +2.72% | 19.13B | 13.89 | $2.45 | +2.53% |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
Stock Comparison
SGMO vs VRTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, VRTX has a market cap of 112.64B. Regarding current trading prices, SGMO is priced at $0.47, while VRTX trades at $438.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas VRTX's P/E ratio is -114.83. In terms of profitability, SGMO's ROE is -3.51%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SGMO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs REGN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, REGN has a market cap of 63.09B. Regarding current trading prices, SGMO is priced at $0.47, while REGN trades at $594.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas REGN's P/E ratio is 15.10. In terms of profitability, SGMO's ROE is -3.51%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SGMO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SGEN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, SGMO is priced at $0.47, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SGMO's ROE is -3.51%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, SGMO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ALNY Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ALNY has a market cap of 37.20B. Regarding current trading prices, SGMO is priced at $0.47, while ALNY trades at $285.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ALNY's P/E ratio is -135.86. In terms of profitability, SGMO's ROE is -3.51%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SGMO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ARGX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ARGX has a market cap of 34.54B. Regarding current trading prices, SGMO is priced at $0.47, while ARGX trades at $565.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ARGX's P/E ratio is 34.47. In terms of profitability, SGMO's ROE is -3.51%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, SGMO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BNTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BNTX has a market cap of 22.30B. Regarding current trading prices, SGMO is priced at $0.47, while BNTX trades at $92.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BNTX's P/E ratio is -26.06. In terms of profitability, SGMO's ROE is -3.51%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SGMO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BGNE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, SGMO is priced at $0.47, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SGMO's ROE is -3.51%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SGMO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RPRX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RPRX has a market cap of 19.13B. Regarding current trading prices, SGMO is priced at $0.47, while RPRX trades at $34.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RPRX's P/E ratio is 13.89. In terms of profitability, SGMO's ROE is -3.51%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SGMO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs DNA-WT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, SGMO is priced at $0.47, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SGMO's ROE is -3.51%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SGMO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SMMT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SMMT has a market cap of 16.78B. Regarding current trading prices, SGMO is priced at $0.47, while SMMT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SMMT's P/E ratio is -66.91. In terms of profitability, SGMO's ROE is -3.51%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SGMO is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs UTHR Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, UTHR has a market cap of 13.77B. Regarding current trading prices, SGMO is priced at $0.47, while UTHR trades at $305.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas UTHR's P/E ratio is 12.17. In terms of profitability, SGMO's ROE is -3.51%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SGMO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs KRTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, SGMO is priced at $0.47, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SGMO's ROE is -3.51%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, SGMO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs EXEL Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, EXEL has a market cap of 12.38B. Regarding current trading prices, SGMO is priced at $0.47, while EXEL trades at $45.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas EXEL's P/E ratio is 25.80. In terms of profitability, SGMO's ROE is -3.51%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SGMO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs GMAB Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, GMAB has a market cap of 12.33B. Regarding current trading prices, SGMO is priced at $0.47, while GMAB trades at $19.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas GMAB's P/E ratio is 11.69. In terms of profitability, SGMO's ROE is -3.51%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SGMO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs INCY Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, INCY has a market cap of 12.25B. Regarding current trading prices, SGMO is priced at $0.47, while INCY trades at $63.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas INCY's P/E ratio is 316.55. In terms of profitability, SGMO's ROE is -3.51%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SGMO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BMRN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BMRN has a market cap of 11.37B. Regarding current trading prices, SGMO is priced at $0.47, while BMRN trades at $59.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BMRN's P/E ratio is 21.95. In terms of profitability, SGMO's ROE is -3.51%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SGMO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MRNA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MRNA has a market cap of 9.61B. Regarding current trading prices, SGMO is priced at $0.47, while MRNA trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MRNA's P/E ratio is -2.85. In terms of profitability, SGMO's ROE is -3.51%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SGMO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RXDX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, SGMO is priced at $0.47, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SGMO's ROE is -3.51%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ASND Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ASND has a market cap of 9.51B. Regarding current trading prices, SGMO is priced at $0.47, while ASND trades at $157.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ASND's P/E ratio is -24.28. In terms of profitability, SGMO's ROE is -3.51%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SGMO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs IMGN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, SGMO is priced at $0.47, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SGMO's ROE is -3.51%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, SGMO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CERE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, SGMO is priced at $0.47, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CERE's P/E ratio is -16.47. In terms of profitability, SGMO's ROE is -3.51%, compared to CERE's ROE of -0.99%. Regarding short-term risk, SGMO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CORT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CORT has a market cap of 7.96B. Regarding current trading prices, SGMO is priced at $0.47, while CORT trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CORT's P/E ratio is 65.29. In terms of profitability, SGMO's ROE is -3.51%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SGMO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ROIVW Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, SGMO is priced at $0.47, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SGMO's ROE is -3.51%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, SGMO is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs TECH Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, TECH has a market cap of 7.71B. Regarding current trading prices, SGMO is priced at $0.47, while TECH trades at $49.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas TECH's P/E ratio is 59.22. In terms of profitability, SGMO's ROE is -3.51%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SGMO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ROIV Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ROIV has a market cap of 7.70B. Regarding current trading prices, SGMO is priced at $0.47, while ROIV trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ROIV's P/E ratio is -10.79. In terms of profitability, SGMO's ROE is -3.51%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, SGMO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RVMD Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RVMD has a market cap of 7.37B. Regarding current trading prices, SGMO is priced at $0.47, while RVMD trades at $39.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RVMD's P/E ratio is -9.86. In terms of profitability, SGMO's ROE is -3.51%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SGMO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs JAZZ Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, JAZZ has a market cap of 6.72B. Regarding current trading prices, SGMO is priced at $0.47, while JAZZ trades at $108.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas JAZZ's P/E ratio is 14.81. In terms of profitability, SGMO's ROE is -3.51%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SGMO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BPMC Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BPMC has a market cap of 6.57B. Regarding current trading prices, SGMO is priced at $0.47, while BPMC trades at $101.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BPMC's P/E ratio is -40.51. In terms of profitability, SGMO's ROE is -3.51%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SGMO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RETA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, SGMO is priced at $0.47, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RETA's P/E ratio is -66.29. In terms of profitability, SGMO's ROE is -3.51%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SGMO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MDGL Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MDGL has a market cap of 6.46B. Regarding current trading prices, SGMO is priced at $0.47, while MDGL trades at $290.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MDGL's P/E ratio is -16.32. In terms of profitability, SGMO's ROE is -3.51%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SGMO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BBIO Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BBIO has a market cap of 6.43B. Regarding current trading prices, SGMO is priced at $0.47, while BBIO trades at $33.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BBIO's P/E ratio is -9.51. In terms of profitability, SGMO's ROE is -3.51%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SGMO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs HALO Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, HALO has a market cap of 6.41B. Regarding current trading prices, SGMO is priced at $0.47, while HALO trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas HALO's P/E ratio is 13.84. In terms of profitability, SGMO's ROE is -3.51%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SGMO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs VRNA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, VRNA has a market cap of 6.06B. Regarding current trading prices, SGMO is priced at $0.47, while VRNA trades at $71.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas VRNA's P/E ratio is -35.65. In terms of profitability, SGMO's ROE is -3.51%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SGMO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs TLX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, TLX has a market cap of 5.58B. Regarding current trading prices, SGMO is priced at $0.47, while TLX trades at $16.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas TLX's P/E ratio is 185.38. In terms of profitability, SGMO's ROE is -3.51%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SGMO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ABCM Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, SGMO is priced at $0.47, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SGMO's ROE is -3.51%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SGMO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ISEE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, SGMO is priced at $0.47, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SGMO's ROE is -3.51%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SGMO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs TGTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, TGTX has a market cap of 5.45B. Regarding current trading prices, SGMO is priced at $0.47, while TGTX trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas TGTX's P/E ratio is 137.44. In terms of profitability, SGMO's ROE is -3.51%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SGMO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs IONS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, IONS has a market cap of 5.34B. Regarding current trading prices, SGMO is priced at $0.47, while IONS trades at $33.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas IONS's P/E ratio is -11.22. In terms of profitability, SGMO's ROE is -3.51%, compared to IONS's ROE of -0.00%. Regarding short-term risk, SGMO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs AXSM Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, AXSM has a market cap of 5.29B. Regarding current trading prices, SGMO is priced at $0.47, while AXSM trades at $107.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas AXSM's P/E ratio is -18.64. In terms of profitability, SGMO's ROE is -3.51%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SGMO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs NUVL Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, NUVL has a market cap of 5.27B. Regarding current trading prices, SGMO is priced at $0.47, while NUVL trades at $73.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas NUVL's P/E ratio is -16.59. In terms of profitability, SGMO's ROE is -3.51%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ALKS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ALKS has a market cap of 5.18B. Regarding current trading prices, SGMO is priced at $0.47, while ALKS trades at $31.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ALKS's P/E ratio is 14.28. In terms of profitability, SGMO's ROE is -3.51%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SGMO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ADMA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ADMA has a market cap of 4.70B. Regarding current trading prices, SGMO is priced at $0.47, while ADMA trades at $19.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ADMA's P/E ratio is 23.44. In terms of profitability, SGMO's ROE is -3.51%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SGMO is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ALPN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, SGMO is priced at $0.47, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SGMO's ROE is -3.51%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, SGMO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs OPT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, SGMO is priced at $0.47, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas OPT's P/E ratio is -1.52. In terms of profitability, SGMO's ROE is -3.51%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SGMO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MRTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, SGMO is priced at $0.47, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SGMO's ROE is -3.51%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, SGMO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs PCVX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, PCVX has a market cap of 4.11B. Regarding current trading prices, SGMO is priced at $0.47, while PCVX trades at $31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas PCVX's P/E ratio is -7.98. In terms of profitability, SGMO's ROE is -3.51%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SGMO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RYTM Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RYTM has a market cap of 3.81B. Regarding current trading prices, SGMO is priced at $0.47, while RYTM trades at $59.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RYTM's P/E ratio is -21.40. In terms of profitability, SGMO's ROE is -3.51%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SGMO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs KRYS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, KRYS has a market cap of 3.77B. Regarding current trading prices, SGMO is priced at $0.47, while KRYS trades at $130.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas KRYS's P/E ratio is 31.32. In terms of profitability, SGMO's ROE is -3.51%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SGMO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RYZB Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, SGMO is priced at $0.47, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SGMO's ROE is -3.51%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SGMO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CBAY Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, SGMO is priced at $0.47, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SGMO's ROE is -3.51%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, SGMO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ACAD Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ACAD has a market cap of 3.73B. Regarding current trading prices, SGMO is priced at $0.47, while ACAD trades at $22.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ACAD's P/E ratio is 16.25. In terms of profitability, SGMO's ROE is -3.51%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SGMO is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs CYTK Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CYTK has a market cap of 3.70B. Regarding current trading prices, SGMO is priced at $0.47, while CYTK trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CYTK's P/E ratio is -5.86. In terms of profitability, SGMO's ROE is -3.51%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SGMO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RNA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RNA has a market cap of 3.66B. Regarding current trading prices, SGMO is priced at $0.47, while RNA trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RNA's P/E ratio is -10.12. In terms of profitability, SGMO's ROE is -3.51%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SGMO is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs PTCT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, PTCT has a market cap of 3.65B. Regarding current trading prices, SGMO is priced at $0.47, while PTCT trades at $46.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas PTCT's P/E ratio is 7.07. In terms of profitability, SGMO's ROE is -3.51%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SGMO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SRPT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SRPT has a market cap of 3.58B. Regarding current trading prices, SGMO is priced at $0.47, while SRPT trades at $36.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SRPT's P/E ratio is -13.80. In terms of profitability, SGMO's ROE is -3.51%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, SGMO is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SWTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SWTX has a market cap of 3.47B. Regarding current trading prices, SGMO is priced at $0.47, while SWTX trades at $46.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SWTX's P/E ratio is -13.52. In terms of profitability, SGMO's ROE is -3.51%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SGMO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs RARE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, RARE has a market cap of 3.37B. Regarding current trading prices, SGMO is priced at $0.47, while RARE trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas RARE's P/E ratio is -6.11. In terms of profitability, SGMO's ROE is -3.51%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SGMO is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CRSP Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CRSP has a market cap of 3.35B. Regarding current trading prices, SGMO is priced at $0.47, while CRSP trades at $38.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CRSP's P/E ratio is -8.63. In terms of profitability, SGMO's ROE is -3.51%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SGMO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs ACLX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ACLX has a market cap of 3.24B. Regarding current trading prices, SGMO is priced at $0.47, while ACLX trades at $58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ACLX's P/E ratio is -19.66. In terms of profitability, SGMO's ROE is -3.51%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SGMO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SLNO Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, SGMO is priced at $0.47, while SLNO trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SLNO's P/E ratio is -15.97. In terms of profitability, SGMO's ROE is -3.51%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SGMO is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs VKTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, VKTX has a market cap of 3.19B. Regarding current trading prices, SGMO is priced at $0.47, while VKTX trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas VKTX's P/E ratio is -24.51. In terms of profitability, SGMO's ROE is -3.51%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SGMO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MTSR Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MTSR has a market cap of 3.10B. Regarding current trading prices, SGMO is priced at $0.47, while MTSR trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MTSR's P/E ratio is -11.67. In terms of profitability, SGMO's ROE is -3.51%, compared to MTSR's ROE of -0.55%. Regarding short-term risk, SGMO is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs AKRO Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, AKRO has a market cap of 3.10B. Regarding current trading prices, SGMO is priced at $0.47, while AKRO trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas AKRO's P/E ratio is -9.82. In terms of profitability, SGMO's ROE is -3.51%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SGMO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CPRX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CPRX has a market cap of 2.97B. Regarding current trading prices, SGMO is priced at $0.47, while CPRX trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CPRX's P/E ratio is 15.52. In terms of profitability, SGMO's ROE is -3.51%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SGMO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CRNX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CRNX has a market cap of 2.93B. Regarding current trading prices, SGMO is priced at $0.47, while CRNX trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CRNX's P/E ratio is -8.47. In terms of profitability, SGMO's ROE is -3.51%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs SRRK Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, SRRK has a market cap of 2.90B. Regarding current trading prices, SGMO is priced at $0.47, while SRRK trades at $30.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas SRRK's P/E ratio is -11.98. In terms of profitability, SGMO's ROE is -3.51%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SGMO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MRUS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MRUS has a market cap of 2.88B. Regarding current trading prices, SGMO is priced at $0.47, while MRUS trades at $41.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MRUS's P/E ratio is -9.99. In terms of profitability, SGMO's ROE is -3.51%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SGMO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MORF Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, SGMO is priced at $0.47, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MORF's P/E ratio is -14.88. In terms of profitability, SGMO's ROE is -3.51%, compared to MORF's ROE of -0.27%. Regarding short-term risk, SGMO is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MOR Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, SGMO is priced at $0.47, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MOR's P/E ratio is -12.64. In terms of profitability, SGMO's ROE is -3.51%, compared to MOR's ROE of +7.43%. Regarding short-term risk, SGMO is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs PTGX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, PTGX has a market cap of 2.76B. Regarding current trading prices, SGMO is priced at $0.47, while PTGX trades at $44.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas PTGX's P/E ratio is 57.04. In terms of profitability, SGMO's ROE is -3.51%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SGMO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs KDNY Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, SGMO is priced at $0.47, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SGMO's ROE is -3.51%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SGMO is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MYOV Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, SGMO is priced at $0.47, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SGMO's ROE is -3.51%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SGMO is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs LEGN Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, LEGN has a market cap of 2.56B. Regarding current trading prices, SGMO is priced at $0.47, while LEGN trades at $27.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas LEGN's P/E ratio is -23.74. In terms of profitability, SGMO's ROE is -3.51%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SGMO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs IBRX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, IBRX has a market cap of 2.51B. Regarding current trading prices, SGMO is priced at $0.47, while IBRX trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas IBRX's P/E ratio is -4.66. In terms of profitability, SGMO's ROE is -3.51%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SGMO is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs IMVT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, IMVT has a market cap of 2.46B. Regarding current trading prices, SGMO is priced at $0.47, while IMVT trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas IMVT's P/E ratio is -5.52. In terms of profitability, SGMO's ROE is -3.51%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, SGMO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs APGE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, APGE has a market cap of 2.42B. Regarding current trading prices, SGMO is priced at $0.47, while APGE trades at $40.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas APGE's P/E ratio is -11.25. In terms of profitability, SGMO's ROE is -3.51%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SGMO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MLTX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MLTX has a market cap of 2.39B. Regarding current trading prices, SGMO is priced at $0.47, while MLTX trades at $37.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MLTX's P/E ratio is -16.36. In terms of profitability, SGMO's ROE is -3.51%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, SGMO is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs PRVB Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, SGMO is priced at $0.47, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SGMO's ROE is -3.51%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SGMO is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs LBPH Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, SGMO is priced at $0.47, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SGMO's ROE is -3.51%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SGMO is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs XENE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, XENE has a market cap of 2.32B. Regarding current trading prices, SGMO is priced at $0.47, while XENE trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas XENE's P/E ratio is -10.06. In terms of profitability, SGMO's ROE is -3.51%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SGMO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs VCYT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, VCYT has a market cap of 2.29B. Regarding current trading prices, SGMO is priced at $0.47, while VCYT trades at $29.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas VCYT's P/E ratio is 94.15. In terms of profitability, SGMO's ROE is -3.51%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SGMO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs DICE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, SGMO is priced at $0.47, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas DICE's P/E ratio is -21.91. In terms of profitability, SGMO's ROE is -3.51%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SGMO is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs MIRM Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, MIRM has a market cap of 2.23B. Regarding current trading prices, SGMO is priced at $0.47, while MIRM trades at $45.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas MIRM's P/E ratio is -27.96. In terms of profitability, SGMO's ROE is -3.51%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SGMO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs APLS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, APLS has a market cap of 2.19B. Regarding current trading prices, SGMO is priced at $0.47, while APLS trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas APLS's P/E ratio is -9.69. In terms of profitability, SGMO's ROE is -3.51%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SGMO is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs ARWR Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, ARWR has a market cap of 2.17B. Regarding current trading prices, SGMO is priced at $0.47, while ARWR trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas ARWR's P/E ratio is -12.67. In terms of profitability, SGMO's ROE is -3.51%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, SGMO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CALT Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, SGMO is priced at $0.47, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CALT's P/E ratio is -22.73. In terms of profitability, SGMO's ROE is -3.51%, compared to CALT's ROE of -2.10%. Regarding short-term risk, SGMO is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BCRX Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BCRX has a market cap of 2.14B. Regarding current trading prices, SGMO is priced at $0.47, while BCRX trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BCRX's P/E ratio is -39.38. In terms of profitability, SGMO's ROE is -3.51%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, SGMO is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs VCEL Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, VCEL has a market cap of 2.14B. Regarding current trading prices, SGMO is priced at $0.47, while VCEL trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas VCEL's P/E ratio is 849.60. In terms of profitability, SGMO's ROE is -3.51%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SGMO is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs NAMS Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, NAMS has a market cap of 2.12B. Regarding current trading prices, SGMO is priced at $0.47, while NAMS trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas NAMS's P/E ratio is -10.26. In terms of profitability, SGMO's ROE is -3.51%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, SGMO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs BLTE Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, BLTE has a market cap of 2.08B. Regarding current trading prices, SGMO is priced at $0.47, while BLTE trades at $64.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas BLTE's P/E ratio is -54.58. In terms of profitability, SGMO's ROE is -3.51%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs AAPG Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, AAPG has a market cap of 2.05B. Regarding current trading prices, SGMO is priced at $0.47, while AAPG trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas AAPG's P/E ratio is -31.86. In terms of profitability, SGMO's ROE is -3.51%, compared to AAPG's ROE of N/A. Regarding short-term risk, SGMO is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs LGND Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, LGND has a market cap of 2.02B. Regarding current trading prices, SGMO is priced at $0.47, while LGND trades at $104.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas LGND's P/E ratio is -14.36. In terms of profitability, SGMO's ROE is -3.51%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SGMO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs HRMY Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, HRMY has a market cap of 2.01B. Regarding current trading prices, SGMO is priced at $0.47, while HRMY trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas HRMY's P/E ratio is 13.39. In terms of profitability, SGMO's ROE is -3.51%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, SGMO is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs DNLI Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, DNLI has a market cap of 2.00B. Regarding current trading prices, SGMO is priced at $0.47, while DNLI trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas DNLI's P/E ratio is -5.16. In terms of profitability, SGMO's ROE is -3.51%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SGMO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs FOLD Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, FOLD has a market cap of 1.98B. Regarding current trading prices, SGMO is priced at $0.47, while FOLD trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas FOLD's P/E ratio is -71.44. In terms of profitability, SGMO's ROE is -3.51%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, SGMO is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.
SGMO vs KYMR Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, KYMR has a market cap of 1.97B. Regarding current trading prices, SGMO is priced at $0.47, while KYMR trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas KYMR's P/E ratio is -9.73. In terms of profitability, SGMO's ROE is -3.51%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SGMO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs NAMSW Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, NAMSW has a market cap of 1.94B. Regarding current trading prices, SGMO is priced at $0.47, while NAMSW trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SGMO's ROE is -3.51%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, SGMO is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs CGON Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, CGON has a market cap of 1.94B. Regarding current trading prices, SGMO is priced at $0.47, while CGON trades at $25.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas CGON's P/E ratio is -16.95. In terms of profitability, SGMO's ROE is -3.51%, compared to CGON's ROE of -0.11%. Regarding short-term risk, SGMO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.
SGMO vs KNSA Comparison
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 109.59M. In comparison, KNSA has a market cap of 1.92B. Regarding current trading prices, SGMO is priced at $0.47, while KNSA trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.96, whereas KNSA's P/E ratio is -43.75. In terms of profitability, SGMO's ROE is -3.51%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SGMO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.